

# Oligodendrocyte-Myelin Glycoprotein and Nogo Negatively Regulate Activity-Dependent Synaptic Plasticity

Stephen J. Raiker,<sup>1,3</sup> Hakjoo Lee,<sup>3\*</sup> Katherine T. Baldwin,<sup>1\*</sup> Yuntao Duan,<sup>1</sup> Peter Shrager,<sup>4</sup> and Roman J. Giger<sup>1,2</sup>

<sup>1</sup>Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, <sup>2</sup>Department of Neurology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, <sup>3</sup>Department of Biomedical Genetics, University of Rochester, Rochester, New York 14642, and <sup>4</sup>Department of Neurobiology and Anatomy, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642

In the adult mammalian CNS, the growth inhibitors oligodendrocyte-myelin glycoprotein (OMgp) and the reticulon RTN4 (Nogo) are broadly expressed in oligodendrocytes and neurons. Nogo and OMgp complex with the neuronal cell surface receptors Nogo receptor-1 (NgR1) and paired Ig-like receptor-B (PirB) to regulate neuronal morphology. In the healthy CNS, NgR1 regulates dendritic spine shape and attenuates activity-driven synaptic plasticity at Schaffer collateral–CA1 synapses. Here, we examine whether Nogo and OMgp influence functional synaptic plasticity, the efficacy by which synaptic transmission occurs. In acute hippocampal slices of adult mice, Nogo-66 and OMgp suppress NMDA receptor-dependent long-term potentiation (LTP) when locally applied to Schaffer collateral–CA1 synapses. Neither Nogo-66 nor OMgp influences basal synaptic transmission or paired-pulse facilitation, a form of short-term synaptic plasticity. *PirB*<sup>-/-</sup> and *NgR1*<sup>-/-</sup> single mutants and *NgR1*<sup>-/-</sup>;*PirB*<sup>-/-</sup> double mutants show normal LTP, indistinguishable from wild-type controls. In juvenile mice, LTD in *NgR1*<sup>-/-</sup>, but not *PirB*<sup>-/-</sup>, slices is absent. Mechanistic studies revealed that Nogo-66 and OMgp suppress LTP in an *NgR1*-dependent manner. OMgp inhibits LTP in part through *PirB* but independently of *p75*. This suggests that NgR1 and PirB participate in ligand-dependent inhibition of synaptic plasticity. Loss of *NgR1* leads to increased phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), signaling intermediates known to regulate neuronal growth and synaptic function. In primary cortical neurons, BDNF elicited phosphorylation of AKT and p70S6 kinase is attenuated in the presence of myelin inhibitors. Collectively, we provide evidence that mechanisms of neuronal growth inhibition and inhibition of synaptic strength are related. Thus, myelin inhibitors and their receptors may coordinate structural and functional neuronal plasticity in CNS health and disease.

## Introduction

Early in postnatal development a number of refinement processes sculpt neuronal connectivity in an experience-dependent manner. A classical example is the formation of ocular dominance (OD) columns in the binocular zone of the primary visual cortex (Katz and Shatz, 1996). During a limited time window called the critical period (CP), experience drives remodeling of synaptic connectivity (Tropea et al., 2009). Beyond the CP, use-dependent changes in neuronal connectivity are less pronounced. More subtle forms of structural neuronal plasticity in the CNS persist throughout adulthood in response to experience, injury, or aging (Florence et al., 1998; Bareyre et al., 2004; Holtmaat and Svoboda, 2009).

Functional synaptic plasticity describes the ability of excitatory synapses to undergo activity-driven long-lasting changes in

the efficacy of synaptic transmission. This change may be expressed as long-term potentiation (LTP) or long-term depression (LTD). A well characterized system for studying long-lasting changes in synaptic transmission is the Schaffer collateral–CA1 synapse of the hippocampus (Bliss and Collingridge, 1993). Prolonged changes in synaptic activity influence neuronal structure, suggesting that structural and functional neuronal plasticity are linked (Yuste and Bonhoeffer, 2001; Schubert and Dotti, 2007).

Components of the Nogo receptor (NgR1) complex have been implicated in activity-dependent refinement of neuronal connectivity in the healthy CNS. NgR1 associates with the growth inhibitory proteins Nogo, OMgp, and MAG and is the ligand binding component of a receptor complex that includes Lingo-1 and p75 or Troy (Xie and Zheng, 2008). In the visual system, *NgR1* and *Nogo-A/B* participate in the consolidation of neuronal connectivity established during the CP (McGee et al., 2005). In the hippocampus, *NgR1* and *p75* regulate dendritic spine morphology (Zagrebelsky et al., 2005; H. Lee et al., 2008). *NgR1* also limits activity-dependent synaptic strength at Schaffer collateral–CA1 synapses (H. Lee et al., 2008), and down-regulation of NgR1 expression is required for consolidation of long-term spatial memory (Karlen et al., 2009).

Evidence suggests that neural major histocompatibility complex class I (MHC1) molecules and their receptors function in activity-dependent synaptic plasticity and structural modification of synaptic connections (Boulanger, 2009). MHC1 mole-

Received Feb. 18, 2010; revised June 17, 2010; accepted July 25, 2010.

This work was supported by National Research Service Award Ruth Kirschstein Fellowship F31NS061589 (S.J.R.), the New York State Spinal Cord Injury Research Program (P.S. and R.J.G.), Schmitt Program on Integrative Brain Research (P.S.), the Dr. Miriam and Sheldon G. Adelson Medical Foundation on Neural Repair and Rehabilitation, the U.S. Department of Veterans Affairs, and National Institute of Neurological Disorders and Stroke Grant R01 NS047333 (R.J.G.). We thank Marc Rothenberg and Melissa Mingler for PirB mutant mice, Rao Praveen for isolation of B cells, and Margaret Youngman for excellent technical assistance.

\*H.L. and K.T.B. contributed equally to this work.

Correspondence should be addressed to Roman J. Giger, Department of Cell and Developmental Biology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109. E-mail: rgiger@umich.edu.

DOI:10.1523/JNEUROSCI.0895-10.2010

Copyright © 2010 the authors 0270-6474/10/3012432-14\$15.00/0

cules *H2-K<sup>b</sup>* and *H2-D<sup>b</sup>* are present in the CNS and limit OD plasticity after monocular deprivation (Datwani et al., 2009). Similarly, loss of the MHC1 receptor *PirB* enhances OD plasticity (Syken et al., 2006). Depletion of MHC1 surface expression results in enhanced LTP and absence of LTD at Schaffer collateral-CA1 synapses (Huh et al., 2000). Remarkably, *PirB* was recently identified as a receptor for Nogo-66, OMgp, and MAG (Atwal et al., 2008). As is the case for *NgR1*, *PirB* signals growth cone collapse in response to acutely presented myelin inhibitors *in vitro*. Moreover, loss of *PirB*, but not *NgR1*, results in enhanced neurite outgrowth on substrate-bound myelin inhibitors.

The unexpected convergence of molecular players that limit experience-dependent neuronal plasticity during normal brain maturation and the molecules that inhibit regenerative sprouting after CNS injury suggests that these two processes are related. To explore this idea further, we examined whether the growth inhibitors Nogo and OMgp influence functional synaptic plasticity in adult neural circuits.

## Materials and Methods

**Transgenic mice.** All animal handling was performed in compliance with local and national animal care guidelines and approved by the University of Rochester Committee on Animal Resources and the University of Michigan Committee on Use and Care of Animals. *NgR1*, *PirB*, and *p75* mutant mice used for our studies have been described previously (K. F. Lee et al., 1992; Ujike et al., 2002; Zheng et al., 2005). The *PirB* mutant mouse line used in this study carries a null allele (Ujike et al., 2002) and is distinct from the transmembrane domain deletion mutant *PirB-TM* (Syken et al., 2006). Mice were housed either in the transgenic core facility of the University of Michigan (*NgR1* and *PirB* colonies) or the University of Rochester (*NgR1*, *PirB*, and *p75* colonies). All mice were kept on a C57BL/6 background and housed in a 12-h light-dark cycle. Mice mutant for *NgR1* and *p75* were genotyped by PCR analysis of tail biopsies (Venkatesh et al., 2007). Primers for *PirB* genotyping included *PirB-5'*, 5'-GTG GCC TTC ATC CTG TTC CTC-3'; *PirB-3'*, 5'-CCT GGT TAT GGG CTC TTC AGC-3'; and *PirB-Neo*, 5'-CTC GTG CTT TAC GGT ATC GCC-3' and were used as described previously (Ujike et al., 2002).

**Reporter gene expression analyses.** In *NgR1* mutant mice, exon 2 of the *NgR1* gene was replaced by a *taulacZ* reporter cassette (Zheng et al., 2005). For *NgR1* reporter gene expression studies, brains from 6- to 8-week-old *NgR1* heterozygous mice (*NgR1<sup>+/taulacZ</sup>*) were quickly removed and flash-frozen in dry ice-cooled isopentane. Cryosections of forebrain tissue were cut at 25  $\mu$ m and mounted on Superfrost-plus microscope slides (Fisher). Sections were rinsed in PBS (137 mM NaCl, 2.7 mM KCl, 1.8 mM KH<sub>2</sub>PO<sub>4</sub>, 1.0 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.4) and developed overnight in 1 mg/ml 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside, 5 mM K<sub>3</sub>Fe(CN)<sub>6</sub>, 5 mM K<sub>4</sub>Fe(CN)<sub>6</sub>, and 2 mM Mg<sup>2+</sup> in PBS at 37°C.

**mRNA *in situ* hybridization.** To visualize the mRNA expression pattern of *PirB* in 3-month-old mouse brain tissue, cryosections (25  $\mu$ m) of wild-type and mutant mice were cut and processed as described previously (Giger et al., 1996). To reduce potential cross-reactivity with *PirA* transcripts, an antisense *PirB* cRNA probe directed against the less conserved C-terminal portion of *PirB* was generated. T7 RNA polymerase was used for *in vitro* run-off transcription of mouse *PirB* cDNA (Open BioSystems) from nucleotides 1736–2526. To confirm specificity of the riboprobe, sections of *PirB* wild-type and mutant brains were processed in parallel.

**Isolation of B cells from spleen.** The spleens from two adult *PirB* wild-type and two mutant mice were dissected, and B cells were isolated as described previously (Sojka et al., 2005). Briefly, spleen cells were incubated with anti-Thy1.2 on ice for 40 min. The Thy1.2 alloantigen is expressed on all thymocytes, peripheral T lymphocytes, and some intraepithelial T cells. Guinea pig complement was added for 25 min at 37°C to lyse Thy1.2-positive cells. The B cells were then collected by two subsequent rounds of low-speed centrifugation in a discontinuous Ficoll gradient. The purity of isolated B cells was assessed by flow cytometry

(FACS Diva 6.0). From spleen, 35.4 million and 32.3 million cells were isolated from *PirB* wild-type and mutant mice, respectively. Cells were sorted by using CD3-Pe and CD4-Pe-Cy7 for T cells and B220-FITC and CD19-APC to label B cells. The purity of B cells was 74% for *PirB<sup>+/+</sup>* and 84% for *PirB<sup>-/-</sup>* spleen.

**Isolation of synaptic density fractions.** Preparation of synaptosomes from mouse or rat brain extracts were carried out as described previously (Phillips et al., 2001). Briefly, mouse neocortices and hippocampi from 3- or 8-week-old *NgR1* wild-type and mutant mice were dissected. In a separate set of experiments hippocampi from 6- to 7-week-old rats were used. Dissected tissue was homogenized in 0.32 M sucrose containing 0.1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.1 mM PMSF, 25 mM NaF, and 1 mM Na<sub>3</sub>VO<sub>4</sub>. Subsequently, 2 M sucrose solution containing 0.1 mM CaCl<sub>2</sub> was added to adjust the final concentration to 1.25 M sucrose. In an ultracentrifuge tube, the 1.25 M sucrose solution containing the tissue homogenate was overlaid with a 1 M sucrose solution containing 0.1 mM CaCl<sub>2</sub> and with 0.32 M sucrose solution containing 0.1 mM CaCl<sub>2</sub>. Synaptosomes were collected at the 1 M/1.25 M interface of the sucrose gradient by centrifugation at 100,000  $\times$  g for 3 h in a Sorvall UltraCentrifuge using a SW41 rotor. From the isolated synaptosomes, the extrasynaptic junction fraction was separated from the synaptic junction proteins by extraction in 1% Triton X-100 at pH 6 followed by centrifugation at 40,000  $\times$  g for 30 min. The resulting pellet comprised the synaptic junction fraction and was further separated into presynaptic and postsynaptic density fractions by extraction in 1% Triton X-100 at pH 8. The protein concentration of each fraction was determined using the BCA kit (Pierce) and adjusted to the same final value. Synaptic density fractions were aliquoted and stored at -80°C. Multiple independent preparations were carried out from *NgR1* wild-type and mutant mice at 6–7 weeks ( $n = 4$ ) and 3 weeks ( $n = 3$ ).

**Recombinant proteins.** Human embryonic kidney (HEK) 293T cells were transiently transfected using Lipofectamine 2000 (Invitrogen) to express enhanced green fluorescent protein (eGFP) or full-length mouse *PirB* (Open Biosystems). Soluble fusion proteins contained either human placental alkaline phosphatase (AP) or the Fc region of human IgG1. Soluble AP-Nogo66 C-terminally tagged with 6-histidines (6his) and AP-Fc were expressed in HEK293T cells and isolated from conditioned cell culture supernatant (OptiMEM; Invitrogen) by affinity chromatography using ProteinA/G beads (Pierce) or Ni<sup>2+</sup>-NTA beads (Invitrogen) as described previously (Venkatesh et al., 2005). Additional recombinant proteins included Nogo66-Fc and OMgp-6his (R&D Systems). The recombinant proteins were analyzed by SDS-PAGE followed by Western blotting or Coomassie staining. In addition, the quality of recombinant proteins was assayed by binding to COS-7 cells transiently transfected with an expression construct for full-length mouse *PirB* or eGFP as described previously (Robak et al., 2009).

**Primary neuronal cultures.** Rat embryonic day 18 (E18) hippocampal and cortical neurons were cultured at high density on poly-L-lysine (50  $\mu$ g/ml)-coated six-well plates in NS21 growth medium (Chen et al., 2008) at 37°C in a humidified cell culture incubator. At day 9 *in vitro* (DIV9), cultures were treated with BDNF (100 ng/ml), crude CNS myelin (185  $\mu$ g/ml) (Robak et al., 2009), or AP-Nogo66 (5 nM) final concentration. AP-Nogo-66 in OptiMEM was added to the cultures, and the same volume of OptiMEM was added to control cultures. Cells were lysed for 20 min on ice using cooled Brij lysis buffer (10 mM potassium phosphate, pH 7.2, 1 mM EDTA, 10 mM MgCl<sub>2</sub>, 50 mM  $\beta$ -glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 0.5% NP40, and 0.1% Brij-35) containing protease inhibitor mixture (Sigma) at a 1:100 dilution. Cell lysates were cleared by centrifugation in a cooled Eppendorf centrifuge for 10 min at maximal speed, and the protein concentration of supernatants was determined with the BCA kit. For Western blot analysis, 10  $\mu$ g of protein lysate was loaded per lane.

**Western blot analysis.** Crude brain homogenates and synaptosomal density fractions were normalized to total protein (BCA kit). Synaptosomes isolated from adult rats or *NgR1* wild-type and mutant mice were lysed in 2 $\times$  Laemmli buffer, separated by SDS-PAGE, and transferred onto nylon membranes. Nitrocellulose membranes were blocked with fat-free milk (2% in TBS-T) and probed with antibodies specific for *NgR1* (1:1000; R&D Systems), Lingo-1 (1:1000; R&D Systems), *p75* (1:1000; Promega), Nogo-A/B (1:500; R&D Systems), OMgp (1:1000; R&D Systems), FGFR1 (kind gift from M. K. Stachowiak, University of Buf-

falo, Buffalo, NY), FRS2 $\alpha$  (1:1000; Santa Cruz Biotechnology), calcium/calmodulin-dependent protein kinase II  $\alpha$  (CamKII $\alpha$ ) (1:1000; Sigma), NR1 (1:1000; Millipore), NR2B (1:1000; Millipore), GluR1 (1:1000; Millipore), syntaxin 1A (1:500; Assay Designs), postsynaptic density-95 (PSD-95) (1:500; Millipore), synaptophysin (1:1000; Sigma), TuJ1 (1:1000; Promega), human Fc (1:1000; Millipore Bioscience Research Reagents), AP (1:5000; American Research Products), and actin (1:10,000; Sigma). To confirm that *PirB* mutant mice are null for PirB protein, lysates of spleen B cells were analyzed by Western blotting with a polyclonal goat anti-PirB antiserum (1:250; R&D Systems). Phospho-specific antibodies and the corresponding phosphorylation-independent antibody were obtained from Cell Signaling and included anti-pAKT(Ser473) (1:2000) and total AKT (1:5000), anti-phosphorylated extracellular signal-regulated kinases 1/2 (p-ERK1/2) (Thr202/Tyr204) (1:2000) and total ERK (1:5000), and anti-pS6K(Thr389) (1:1000) and total S6K (1:1000). To detect all of these antibodies ECL anti-rabbit, anti-goat, or anti-mouse secondary IgG-HRP (from donkey; GE Healthcare) at 1:3000 was used. For Western blots with the phospho-specific antibodies, PVDF membrane (from Millipore) was blocked with 2% TBS-T (0.1% Tween), and the same buffer was used for antibody dilution.

**Electrophysiological recordings.** Recordings from acute hippocampal slices were performed as described previously (H. Lee et al., 2008). Briefly, for LTP experiments *NgR1*, *PirB*, or *p75* mutant and wild-type mice between 6 and 9 weeks of age were decapitated, and the brains were quickly removed and immediately placed in ice-cold artificial CSF (ACSF: 125 mM NaCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 25 mM glucose, 25 mM NaHCO<sub>3</sub>, 2.5 mM CaCl<sub>2</sub>, 1.3 mM MgCl<sub>2</sub>, 2.5 mM KCl saturated with 95% O<sub>2</sub>/5% CO<sub>2</sub>). For LTD studies brains from postnatal day (P) 15–P17 mice or P18–P21 rat pups were used as described in detail (H. Lee et al., 2008). For all recordings at CA3–CA1 synapses sagittal slices (400  $\mu$ m) were cut on a vibrating microtome and maintained in oxygenated (95% O<sub>2</sub>/5% CO<sub>2</sub>) ACSF at room temperature for at least 1.5 h. For recordings, the slices were transferred to a heated immersion chamber, continuously perfused at 3 ml/min with oxygenated ACSF, and maintained at 32  $\pm$  0.5°C.

Evoked potentials were recorded from the CA1 stratum radiatum region by stimulating Schaffer collateral afferents with a platinum/iridium concentric bipolar electrode (FHC Inc). Field EPSPs (fEPSPs) were taken with glass microelectrodes filled with ACSF (pipette resistance  $\sim$ 0.3–0.4 M $\Omega$ ). The stimulation electrode was positioned in the Schaffer collateral projections to provide activation of the CA1 pyramidal cells. Input–output (I/O) curves were established using a stimulus amplitude of 50, 100, or 150  $\mu$ A. Slices were monitored with stimuli consisting of constant current pulses of 0.1-ms duration at 0.067 Hz. After baseline recording for  $\sim$ 45 min ( $\sim$ 1-mV amplitude), LTP was induced at  $\leq$ 50% of maximal amplitude by high-frequency stimulation (HFS) (100 Hz, 1-s duration, two trains, interval 10 s) as described previously (Meng et al., 2003). Slices that did not show a stable baseline for at least 30 min before stimulation were discarded. For local application of recombinant protein to the dendritic field of CA1 neurons, OMgp, Nogo-66, or AP-Fc were diluted in ACSF to a final concentration of 0.5–1 mg/ml, loaded in the recording pipette, and applied locally as described previously (H. Lee et al., 2008). For paired-pulse facilitation (PPF) recordings, interpulse interval durations of 25, 50, 100, 200, 300, 400, and 500 ms were used, and recordings in the presence or absence of locally applied ligand were performed as described previously (H. Lee et al., 2008).

LTD experiments were carried out in a similar fashion on acute slices from P15–P20 mouse pups except that MgCl<sub>2</sub> and KCl concentrations were increased to 2.0 and 5.0 mM, respectively (H. Lee et al., 2008). To induce depression of the fEPSP a low-frequency stimulus comprised of 900 pulses given at 1 Hz for a total duration of 15 min was applied. For local application of recombinant protein to the dendritic field of CA1 neurons, proteins of interest were loaded in the recording electrode as described above.

**Data acquisition and analysis.** Recorded potentials were filtered at 3 kHz, digitized at 12.5 kHz, and stored for later analysis. fEPSPs were analyzed by fitting third-order polynomials to the sweeps, first to measure the peak, and then to measure the slope at the 50% amplitude point. All fits were monitored visually on the oscilloscope screen. Data were normalized to the baseline average. Electrophysiological measurements are presented as

mean percentile of baseline  $\pm$  SEM. Data were analyzed statistically using Student's *t* test. Significance was determined as *p* < 0.05.


## Results

### Reporter gene expression analyses reveal *NgR1* promoter activity in hippocampal CA1 pyramidal cells and dentate granule neurons

Previous studies showed that loss of *NgR1* results in a dendritic spine phenotype in adult hippocampal CA1 neurons. Compared with age-matched wild-type mice, the spine morphology profile of *NgR1* mutants appears more immature, indicating that *NgR1* functions in dendritic spine maturation or stabilization (H. Lee et al., 2008). Electrophysiological studies further revealed that *NgR1* is important for the induction and expression of LTD and FGF2-dependent regulation of LTP at Schaffer collateral–CA1 synapses (H. Lee et al., 2008). To assess *NgR1* expression in the adult mouse brain, we took advantage of an existing *NgR1*<sup>*taulacZ*</sup> reporter mouse (Zheng et al., 2005). Consistent with *NgR1* mRNA expression studies (Hunt et al., 2002; Josephson et al., 2003; Barrette et al., 2007), *taulacZ* reporter gene expression was strongest in the hippocampus, neocortex, dorsal thalamus, basolateral amygdala, and superficial layers of the piriform cortex (Fig. 1A). In addition,  $\beta$ -galactosidase labeling was detected in several major fiber systems, indicating that the *NgR1* promoter is active in different types of CNS projection neurons. Fiber systems with strong labeling included the optic tract, corpus callosum, internal capsule, fimbria, and fornix (Fig. 1A). In the hippocampus, strong labeling was detected in the CA1 dendritic field, the alveus, and presumptive fibers of the temporoammonic pathway. The temporoammonic pathway to CA1 provides input directly from layer III of the entorhinal cortex onto distal dendrites of CA1 pyramidal cells in the stratum lacunosum moleculare (Fig. 1B). Somewhat weaker labeling was observed in the outer rim of the molecular layer of the dentate gyrus and along dentate mossy fiber projections (Fig. 1A,B). Very little, if any,  $\beta$ -galactosidase activity was detected in the CA3 pyramidal cell layer and Schaffer collaterals (Fig. 1B). Together, these findings reveal that the *NgR1* promoter is active in distinct regions of the mature brain and suggest that *NgR1* is expressed in specific populations of CNS projection neurons. In the hippocampus strongest labeling was detected in CA1 pyramidal cells and axons of the temporoammonic pathway.

### OMgp and Nogo-A, but not Nogo-B, are present in presynaptic and postsynaptic density fractions

Although most attention has focused on the role of Nogo-A and OMgp as myelin-derived inhibitors of axonal growth and regeneration after CNS injury, Nogo-A and OMgp expression is not confined to oligodendrocytes. OMgp and Nogo-A are abundantly found in various types of neurons in the developing and mature CNS (Josephson et al., 2001; Huber et al., 2002; H. Lee et al., 2008; J. K. Lee et al., 2009; Gil et al., 2010). Ultrastructural analyses revealed that Nogo-A and *NgR1* are present at presynaptic and postsynaptic sites in the mature rat neocortex (Wang et al., 2002). In addition, *NgR1* and Nogo-A were found in synaptosomal density fractions prepared from juvenile and adult rat hippocampus (H. Lee et al., 2008; Grunewald et al., 2009). Similarly, a synaptic association for OMgp in mouse forebrain has been reported (Gil et al., 2009). *PirB*, a recently discovered receptor for Nogo, OMgp, and MAG, is expressed in the CNS (Atwal et al., 2008) and was found in synaptosomes isolated from whole mouse brain extracts (Syken et al., 2006). Double-immunofluorescence labeling of



**Figure 1.** Distribution of myelin inhibitors and their receptors in brain. **A**, *NgR1<sup>+/tauacZ</sup>* reporter gene expression analysis of coronal brain tissue section. Strong  $\beta$ -galactosidase staining is observed in the neocortex, dorsal thalamus (DT), superficial layers of the piriform cortex (PC), and basolateral amygdala (BLA). Several major fibers systems show strong  $\beta$ -galactosidase staining including the internal capsule (ic), corpus callosum (cc), optic tract (ot), fimbria (fi), and fornix (fo). **B**, Higher magnification of the hippocampus shows labeling of the dendritic field of CA1 pyramidal neurons, fibers of the temporoammonic pathway (ta), alveus (arrows), and presumptive mossy fiber projections (dotted line). Of note, no reporter gene expression was observed in the CA3 pyramidal cell layer or Schaffer collateral projections. **C**, *In situ* hybridization with an antisense *PirB* probe shows weak labeling in the adult mouse neocortex. Higher levels of *PirB* expression are observed in the dentate gyrus and CA3–CA1 pyramidal layer. **D**, The same *PirB* antisense probe shows no labeling on adult *PirB*<sup>-/-</sup> mouse brain tissue sections. Scale bars: **A**, 1 mm; **B**, 150  $\mu$ m; **C**, **D**, 300  $\mu$ m. **E**, Distribution of NgR1, Nogo-A, Nogo-B, OMgp, and p75 in synaptic density fractions prepared from adult rat hippocampi. Markers for different synaptic fractions included synaptophysin and PSD-95. Abbreviations: homog, hippocampal homogenate; synapto, synaptosomal fraction; extra-SJ, extrasynaptic junction; SJ, synaptic junction; pre, presynaptic fraction; post, postsynaptic fraction. **F**, Anti-*PirB* immunoblotting of B cells isolated from WT or *PirB*<sup>-/-</sup> spleen. No *PirB* protein is detected in *PirB*<sup>-/-</sup> spleen homogenates. Anti-actin is shown as a loading control.

primary cortical neurons revealed that *PirB* is present at or near synaptic sites (Syken et al., 2006).

To independently assess the distribution of *PirB* in the neocortex and hippocampus, we performed *in situ* hybridization to visualize *PirB* transcripts in adult mouse brain tissue. In the hippocampus, dentate granule cells are labeled and somewhat less intense staining is found in CA3 and CA1 neurons. Weak labeling was found in the adult neocortex. As a specificity control, brain sections of age-matched *PirB* mutants were processed in parallel. No labeling was detected in brain tissue sections of *PirB* mutants (Fig. 1C,D). Consistent with a previous report (Ujike et al., 2002), these *PirB* mutants are null for *PirB*. No *PirB* protein was detected by Western blot analysis of mutant B cells (Fig. 1F).

Next, we assessed the subcellular distribution of Nogo-A, Nogo-B, OMgp, and p75 in the hippocampus compared with *NgR1*. Synaptosomes were isolated from adult rat hippocampal homogenates and then further separated into synaptic density fractions (Fig. 1E). To ensure the quality of the biochemical fractionation, antibodies specific for the synaptic markers synaptophysin (extrasynaptic junction) and PSD-95 (postsynaptic fraction) were used. As shown in Figure 1E, *NgR1*, Nogo-A, and OMgp are abundantly present in presynaptic and postsynaptic density fractions. Nogo-B is abundant in brain homogenates, synaptosomes, and extrasynaptic junction fractions, but is absent from synaptic junction and presynaptic and postsynaptic density fractions. This suggests that only Nogo-A, but not the splice variant Nogo-B, is present at hippocampal synapses. Consistent with a previous report (Barrett et al., 2005), p75 is very sparsely expressed in the mature rat hippocampus and largely confined to septo-hippocampal fibers. Collectively, these studies show that Nogo-A and OMgp and their high-affinity binding partners, *NgR1* (H. Lee et al., 2008) and *PirB* (Syken et al., 2006), are expressed in the adult brain and localized to synaptic and extrasynaptic sites. Nogo-A and OMgp are found in presynaptic and postsynaptic density fractions, and both proteins appear to be somewhat enriched postsynaptically. Thus, biochemical studies are consistent with the idea that Nogo-A, OMgp, *NgR1*, and *PirB* are present at synaptic sites where they may interact with each other to influence synaptic function.

### OMgp inhibits LTP after tetanic stimulation

Thus far, our studies indicate that Nogo-A and OMgp are expressed in the hippocampus and present in presynaptic and postsynaptic density fractions. These findings, coupled with our previous observation that *NgR1* functions as a FGF2-dependent regulator of hippocampal LTP at CA3–CA1 synapses (H. Lee et al., 2008), prompted us to investigate whether *NgR1* ligands other than FGF2 have the potential to modulate synaptic plasticity. In a first set of experiments, recombinant OMgp was locally applied to Schaffer collateral–CA1 synapses of acute hippocampal slices prepared from adult wild-type mice. After baseline recording for >30 min, LTP was induced by two trains of HFS (100 Hz; 1 s; separated by a 10-s interval), which resulted in a sustained increase in the slope of the fEPSP. The mean fEPSP slope 55–60 min after HFS was measured as a percentage of baseline. In the absence of exogenously applied ligand, LTP of synaptic transmission in wild-type mice was robust and stable at  $171 \pm 2\%$  compared with baseline (100%). The LTP recorded is NMDA receptor (NMDAR)-dependent because it is blocked completely in the presence of the NMDAR antagonist 2-amino-5-phosphonovalerate (50  $\mu$ M) added to the slice perfusion solution (data not shown).


Analogous to our previous experiments with FGF2 (H. Lee et al., 2008), soluble OMgp was loaded into the recording pipette and locally applied to the dendritic field of CA1 neurons. In the presence of OMgp, LTP in response to HFS was significantly decreased (fEPSP:  $130 \pm 8\%$ ;  $p < 0.05$ ) compared with no-ligand control slices (Fig. 2A). As an additional control, human placental alkaline phosphatase fused to the Fc region of human IgG1 (AP-Fc), was locally applied via the recording electrode to the dendritic field of CA1 neurons (Fig. 2B). As was the case for no-ligand control slices, LTP at 55–60 min after HFS in AP-Fc-treated slices was robust (fEPSP:  $162 \pm 6\%$ ) and significantly higher compared with OMgp-treated slices ( $p < 0.05$ ) (Fig. 2C). Together, these results show that OMgp attenuates activity-dependent synaptic strength at Schaffer collateral–CA1 synapses.

Next, to examine whether acute treatment with OMgp had a direct effect on basal neurotransmission, we assessed basal synaptic function by constructing I/O curves in the presence or absence of locally applied OMgp. I/O curves were generated by measuring fEPSP evoked by stimulation of Schaffer collateral projections with different stimulus intensities. As shown in Figure 2*D*, the application of OMgp had no effect on the single stimulus-evoked responses across the range of stimuli tested. This suggests that acute application of OMgp does not significantly alter basal synaptic transmission.

Because OMgp is present in presynaptic and postsynaptic density fractions (Fig. 1*E*), it is not apparent whether OMgp functions presynaptically or postsynaptically at the CA3–CA1 synapse. To address whether OMgp is likely to influence presynaptic function, we measured PPF in the presence or absence of exogenously applied OMgp. PPF is a presynaptically driven form of short-term plasticity that measures transient enhancement of neurotransmitter release induced by two closely spaced stimuli attributable to accumulation of intracellular calcium (Schulz et al., 1994). We measured PPF at interstimulus intervals of 25–500 ms and observed maximal facilitation at time intervals between 25 and 100 ms. Upon exposure to OMgp, no significant difference ( $p > 0.05$ ) was observed in PPF at any interstimulus interval tested (Fig. 2*E, F*). This indicates that OMgp does not influence the presynaptic neurotransmitter release probability and suggests that OMgp functions via a postsynaptic mechanism to attenuate LTP of synaptic transmission.

### OMgp does not alter induction or expression of LTD

LTP and LTD of synaptic transmission are reciprocal forms of long-lasting changes in synaptic activity that adapt neuronal transmission to external experience. In response to high levels of synaptic activity, a synapse can increase both the level of neurotransmitter release and the amplitude of the postsynaptic response. Conversely, low-frequency stimulation (LFS) over several minutes can result in weakening or depression of synaptic activity. Because *NgR1* is important for the expression of LTD at CA3–CA1 synapses (H. Lee et al., 2008), we wondered whether OMgp influences synaptic plasticity of the LTD type. LTD of synaptic transmission was induced in acute hippocampal slices from P18–P21 rat pups by LFS at 1 Hz, 900 pulses. In no-ligand control slices, LFS resulted in a prolonged (>1 h) and significant depression of the fEPSP slope compared with baseline ( $79 \pm 3\%$ ;  $p < 0.05$ ) (Fig. 2*G*). As was the case for no-ligand control slices, hippocampal slices locally treated with OMgp showed a significant ( $p < 0.05$ ) and lasting decrease in their fEPSP slope ( $84 \pm 5\%$ ) (Fig. 2*G*). Quantification of LTD at 55–60 min after LFS re-




**Figure 2.** OMgp inhibits hippocampal LTP. Recordings of fEPSPs at Schaffer collateral–CA1 synapses in acute hippocampal slices of 6- to 8-week-old wild-type mice. **A**, Slices were treated with OMgp locally applied via the recording pipette to the dendritic field of CA1 neurons. Summary of LTP recordings in the absence (–OMgp; blue squares) or presence (+OMgp; red triangles) of OMgp are shown. fEPSPs were recorded at CA1 synapses, and slopes were plotted against time before and after tetanic stimulation (two trains of stimuli at 100 Hz for 1 s, separated by a 10-s interval). In the absence of OMgp, the mean fEPSP at 55–60 min was  $171 \pm 2\%$  of baseline ( $n = 8$  slices/6 animals). In the presence of OMgp, the mean fEPSP at 55–60 min was  $130 \pm 8\%$  of baseline ( $n = 6$  slices/3 animals). The concentration of OMgp in the recording electrode was 1 mg/ml. **B**, In parallel experiments, hippocampal slices were treated with the control protein AP-Fc. As was done for OMgp, AP-Fc (1 mg/ml) was loaded in the recording electrode and locally applied to CA1 dendritic field. LTP in the absence (–AP-Fc; blue squares) or the presence (+AP-Fc; red triangles) of AP-Fc is very similar. In the absence of AP-Fc, the mean fEPSP at 55–60 min is  $157 \pm 10\%$  of baseline ( $n = 6$  slices/4 animals), and in the presence of AP-Fc, the mean fEPSP at 55–60 min is  $162 \pm 6\%$  of baseline ( $n = 7$  slices/5 animals). Insets, Representative traces collected before and after HFS are shown. **C**, Quantification of LTP at 55–60 min after HFS in the presence or absence of locally applied OMgp or AP-Fc. Statistical analysis was performed using Student's *t* test. \* indicates significance,  $p < 0.05$ . All error bars are SEMs. **D**, I/O curves for basal synaptic transmission revealed no differences in fEPSP amplitudes between slices treated with OMgp ( $n = 9$  slices/4 animals) compared with untreated (no-ligand) slices ( $n = 6$  slices/4 animals). **E**, PPF in wild-type slices in the absence (–OMgp; blue squares) or presence (+OMgp; red triangles) of OMgp. Inset shows traces collected from experiments with an interpulse interval of 50 ms. **F**, Quantification of PPF experiments. The increase in the second fEPSP amplitude over the first fEPSP amplitude was calculated in the presence or absence of locally applied OMgp, and the mean values were plotted against interpulse intervals at 25 and 50 ms. No significant difference was observed at these interpulse intervals. **G**, Summary of LTD experiments after LFS (900 pulses; 1 Hz) in P18–P21 rat slices in the absence (–OMgp; blue squares) or presence (+OMgp; red triangles) of OMgp applied via the recording electrode. Evoked fEPSP slope ratios are shown as a function of time. Representative traces before and after LTD are shown as insets. In the presence of OMgp (red triangles), the mean fEPSP was  $79 \pm 3\%$  of baseline ( $n = 5$  slices/3 animals) and in the absence of OMgp (blue squares) the mean fEPSP was  $84 \pm 5\%$  of baseline ( $n = 3$  slices/2 animals). For insets in **A**, **B**, **E**, and **G**, calibration is 0.5 mV, 5 ms. **H**, Quantification of LTD at 55–60 min after LFS (blue: no OMgp; red: OMgp was locally applied). n.s. indicates not significant;  $p > 0.05$ . Error bars are SEMs.

vealed no statistically significant difference between OMgp and no-ligand treated slices ( $p = 0.88$ ) (Fig. 2*H*). These results indicate that in the presence of acutely applied OMgp LTD at CA3–CA1 synapses is not altered. In sum, the data suggest that in wild-type hippocampal slices OMgp inhibits LTP-type, but not LTD-type, synaptic plasticity.

### Nogo-66 functions as a negative regulator of hippocampal LTP

Like OMgp, Nogo-A is present at synapses (Wang et al., 2002; H. Lee et al., 2008). To examine whether the Nogo inhibitory peptide Nogo-66 influences functional synaptic plasticity, soluble Nogo-66 was loaded into the recording pipette and locally ap-



**Figure 3.** Nogo-66 inhibits LTP. **A**, Nogo-66 was loaded into the recording pipette (1 mg/ml) and locally applied to the dendritic field of CA1 neurons. Summary of LTP recordings after tetanic stimulation ( $t = 0$  min) of hippocampal slices in the absence (blue squares) or presence (red triangles) of acutely applied Nogo-66 is shown. Nogo-66-treated slices (mean fEPSP,  $136 \pm 7\%$ ,  $n = 11$  slices/9 animals) show significantly decreased LTP ( $p < 0.05$ ) compared with no-ligand slices (mean fEPSP,  $171 \pm 2\%$  of baseline,  $n = 8$  slices/6 animals). Insets, Representative traces before and after HFS are shown. Calibration is 0.5 mV, 5 ms. **B**, Quantification of LTP at 55–60 min after HFS in the absence (blue) or presence (red) of Nogo-66 revealed a significant decrease in LTP. Baseline is indicated by a dotted line. **C**, Acutely applied Nogo-66 does not alter basal synaptic transmission at Schaffer collateral–CA1 synapses. I/O curves were constructed in the absence (–Nogo66; blue squares) or presence (+Nogo66; red triangles) of Nogo-66 and do not show a significant difference at any stimulus amplitude tested ( $n = 7$  slices/4 animals). **D**, PPF in wild-type slices in the absence (–Nogo-66; blue squares) or presence (+Nogo-66; red triangles) of Nogo-66. The increase in the second fEPSP amplitude over the first fEPSP amplitude was calculated in the presence or absence of locally applied Nogo-66, and the mean values were plotted against different interpulse intervals (25–500 ms). No significant difference was observed at any of the interpulse intervals. Insets show traces collected from experiments with an interpulse interval of 50 ms. Calibration is 0.5 mV, 5 ms. **E**, Quantification of PPF ratios at 25 and 50 ms in the absence (blue) or presence (red) of Nogo-66 is shown. Statistical analysis was performed using Student's *t* test. \* indicates significance,  $p < 0.05$ . n.s. indicates not significant. All error bars are SEMs.

plied to the CA1 dendritic field of pyramidal cells in acute mouse hippocampal slices. Like OMgp, focal application of Nogo-66 leads to a significant suppression of LTP (fEPSP;  $136 \pm 7\%$ , compared with control slices (fEPSP;  $171 \pm 2\%$ ;  $p < 0.05$ ) (Fig. 3A,B). Additional experiments showed that Nogo-66 has no apparent effect on basal synaptic transmission as assessed by comparing I/O curves constructed in the presence or absence of locally applied Nogo-66 (Fig. 3C). PPF ratios were indistinguishable between no-ligand and Nogo-66-treated slices, indicating that Nogo-66 does not influence the presynaptic neurotransmitter release machinery (Fig. 3D,E). These data suggest that neither OMgp nor Nogo-66 influences PPF, a form of presynaptically driven short-term plasticity. Thus, the inhibitory effects of Nogo-66 and OMgp on LTP are likely to be the result of postsynaptic mechanisms. Collectively, our studies uncover a novel function for OMgp and Nogo-66 at CNS synapses. In addition to their roles in limiting neuronal growth and sprouting, OMgp and Nogo-66 have the capacity to inhibit activity-driven synaptic plasticity of the LTP type.

#### OMgp and Nogo-66 suppress LTP in a *NgR1*-dependent manner

To explore the possibility that OMgp and Nogo-66 suppress LTP in an *NgR1*-dependent manner, recordings were repeated with hippocampal slices prepared from 6- to 8-week-old *NgR1* mutant (*NgR1*<sup>−/−</sup>) mice. Previously, we reported that genetic ablation of

*NgR1* does not alter the induction or maintenance of LTP at the CA3–CA1 synapse in acute hippocampal slices (H. Lee et al., 2008). Furthermore, overexpression of *NgR1* in hippocampal neurons does not lead to significantly altered LTP at CA3–CA1 synapses (Karlen et al., 2009). As shown previously (H. Lee et al., 2008), HFS of Schaffer collaterals in acute hippocampal slices of *NgR1*<sup>−/−</sup> mice leads to robust LTP (fEPSP:  $170 \pm 8\%$ ) that is indistinguishable from LTP observed in age-matched wild-type (*NgR1*<sup>+/+</sup>) slices (fEPSP:  $171 \pm 2\%$ ). We tested acute treatment of *NgR1*<sup>−/−</sup> hippocampal slices with either OMgp or Nogo-66 and found that these ligands no longer result in a significant decrease in LTP (Fig. 4A–D). In *NgR1*<sup>−/−</sup> slices, tetanic stimulation in the presence of OMgp (fEPSP:  $159 \pm 10\%$ ) and Nogo-66 (fEPSP:  $175 \pm 12\%$ ) results in synaptic potentiation levels comparable with those observed from recordings of *NgR1*<sup>+/+</sup> slices (fEPSP:  $171 \pm 2\%$ ) or *NgR1*<sup>−/−</sup> slices without acutely applied ligand (fEPSP:  $170 \pm 8\%$ ). Statistical analyses revealed that neither OMgp ( $p = 0.37$ ) nor Nogo-66 ( $p = 0.46$ ) causes a significant decrease in LTP in *NgR1*<sup>−/−</sup> mutant slices (Fig. 4B,D). Thus, our experiments indicate that OMgp- and Nogo-66-mediated inhibition of hippocampal LTP is *NgR1*-dependent. Collectively, these observations suggest that *NgR1* functions as a neuronal receptor for Nogo and OMgp, eliciting a suppression of activity-dependent synaptic strength.

#### *p75*-independent mechanisms for OMgp-mediated suppression of LTP

*NgR1* is a glycosylphosphatidylinositol-anchored membrane protein and thus depends on interactions with transmembrane-spanning proteins to convey a signal across the neuronal plasma membrane upon ligand binding. The low-affinity neurotrophin receptor *p75* complexes with *NgR1*, and in some neurons *p75* is important to signal myelin inhibition of neurite outgrowth (Yiu and He, 2006). Like *NgR1* mutants, acute slices derived from *p75* mutant mice show a deficit in the induction of LTD without any changes in LTP (Woo et al., 2005). To test directly whether *p75* plays a role in OMgp-mediated suppression of hippocampal LTP, OMgp was focally applied to the CA1 dendritic field of acute hippocampal slices of *p75* wild-type (*p75*<sup>+/+</sup>) and mutant (*p75*<sup>−/−</sup>) mice. As was the case for wild-type slices treated with OMgp (fEPSP:  $130 \pm 3\%$ ), *p75*<sup>−/−</sup> slices treated with OMgp (fEPSP:  $127 \pm 2\%$ ) showed significantly lower levels of synaptic potentiation than slices treated with ACSF only (fEPSP:  $166 \pm 11\%$ ). Compared with no-ligand control slices, LTP in the presence of OMgp was significantly decreased for both *p75*<sup>+/+</sup> ( $p < 0.05$ ) and *p75*<sup>−/−</sup> ( $p < 0.05$ ) hippocampal slices (Fig. 4E,F). Together, our results show that OMgp-mediated suppression of LTP is *NgR1*-dependent and *p75*-independent. Thus, with respect to myelin inhibitor-mediated suppression of LTP in CA1


neurons our mechanistic studies revealed that *NgR1* and *p75* function can be dissociated.

### Normal LTP in *PirB* mutant mice


*PirB* is a receptor for Nogo, MAG, and OMgp that mediates neurite outgrowth inhibition *in vitro* (Atwal et al., 2008). In the immune system, *PirB* functions as an inhibitory MHC class I receptor on B cells and myeloid cells (Takai, 2005). Mice deficient for  $\beta 2m/TAP1$  show markedly reduced surface expression of most MHC1 molecules (Dorfman et al., 1997), and their hippocampal LTP at CA3–CA1 synapses is enhanced, whereas LTD is absent (Huh et al., 2000). These experiments provide indirect evidence that MHC1 molecules are important regulators of activity-dependent synaptic strength. Multiple MHC1 receptors have been identified, several of which are prominently expressed in the CNS (Corriveau et al., 1998). Loss of the MHC1 receptor component CD3 $\zeta$  leads to an enhancement of LTP and loss of LTD (Huh et al., 2000). Whether loss of *PirB* or other MHC1 receptors results in impaired hippocampal plasticity has not yet been examined. Because *PirB* is expressed in the adult hippocampus (Fig. 1) and several of its ligands have been implicated in activity-dependent regulation of synaptic plasticity, including OMgp (Fig. 2), Nogo (Fig. 3), and MHC1 (Huh et al., 2000), we wanted to assess whether LTP at Schaffer–collateral CA1 synapses is altered between *PirB* wild-type (*PirB*<sup>+/+</sup>) and mutant (*PirB*<sup>-/-</sup>) mice.

Basal transmission at Schaffer collateral–CA1 synapses was indistinguishable between slices prepared from *PirB*<sup>+/+</sup> and age-matched *PirB*<sup>-/-</sup> mice as assessed by I/O curves. No changes in single stimulus-evoked responses were observed between the two genotypes, suggesting that loss of *PirB* does not influence basal synaptic transmission (Fig. 5A). PPF, a presynaptically driven form of short-term plasticity, is indistinguishable between *PirB*<sup>+/+</sup> and age-matched *PirB*<sup>-/-</sup> hippocampal slices. As shown in Figure 5B, PPF ratios were plotted over a stimulus interval of 25–500 ms. The strongest facilitation occurred between 50 and 100 ms. No significant difference in PPF was observed between *PirB*<sup>+/+</sup> and *PirB*<sup>-/-</sup> slices at any of the tested interpulse intervals (Fig. 5B,E) ( $p > 0.05$ ).

To examine whether loss of *PirB* influences activity-driven synaptic plasticity, tetanus-induced LTP was recorded from acute hippocampal slices of 6- to 8-week-old *PirB*<sup>+/+</sup> and *PirB*<sup>-/-</sup> mice. LTP at CA3–CA1 synapses was induced by two bursts of HFS (100 Hz; 1 s; separated by a 10-s interval), and potentiation at 55–60 min past HFS was quantified (Fig.



5C,D). Interestingly, LTP of *PirB* mutants (fEPSP:  $157 \pm 6\%$ ) was robust and indistinguishable from that of *PirB* wild-type mice (fEPSP:  $157 \pm 8\%$ ) (Fig. 5C, $p = 0.99$ ). These data reveal that loss of *PirB* does not result in altered LTP at CA3–CA1 synapses. Thus, loss of *PirB* does not mimic the enhanced LTP phenotype reported for  $\beta 2m/TAP1$  double mutants, mice with greatly reduced surface expression of MHC1 molecules (Huh et al., 2000).



**Figure 5.** Genetic ablation of *PirB* does not result in altered LTP of synaptic transmission. **A**, I/O curves for basal synaptic transmission revealed no differences in fEPSP amplitudes between wild-type (*PirB*<sup>+/+</sup>; blue squares) and mutant (*PirB*<sup>-/-</sup>; red triangles) hippocampal slices. **B**, PPF in *PirB*<sup>+/+</sup> and *PirB*<sup>-/-</sup> slices. The increase in the second fEPSP amplitude over the first fEPSP amplitude was calculated, and the mean values were plotted against different interpulse intervals (25–500 ms). No significant difference was observed at any of the interpulse intervals. Insets show traces collected from experiments with an interpulse interval of 50 ms. Calibration is 0.5 mV, 5 ms. **C**, Summary of LTP recordings after HFS stimulation ( $t = 0$  min) of acute hippocampal slices of 6- to 8-week-old *PirB*<sup>+/+</sup> (blue squares) and *PirB*<sup>-/-</sup> (red triangles) mice. **D**, Quantification of mean fEPSP at 55–60 min after HFS. LTP is not enhanced in *PirB*<sup>-/-</sup> mice (blue; mean fEPSP  $157 \pm 6\%$  of baseline,  $n = 14$  slices/6 animals) compared with *PirB*<sup>+/+</sup> mice (red; mean fEPSP  $157 \pm 8\%$  of baseline,  $n = 7$  slices/4 animals). Baseline is marked by dotted line. **E**, Quantification of PPF ratios at 25 and 50 ms in *PirB*<sup>+/+</sup> (blue) or *PirB*<sup>-/-</sup> (red) slices. Statistical analysis was performed using Student's *t* test. n.s. indicates not significantly different ( $p > 0.05$ ). All error bars are SEMs.

### Loss of *PirB* attenuates OMgp-mediated inhibition of LTP

*In vitro*, NgR1 and PirB collaborate to signal neurite outgrowth inhibition. Genetic ablation of *PirB* or bath application of anti-PirB partially attenuates myelin inhibition of primary neurons. The combined ablation of PirB and NgR1 virtually abolishes neurite outgrowth inhibition in the presence of crude CNS myelin (Atwal et al., 2008). Furthermore, growth cone collapse assays revealed that PirB and NgR1 function as codependent receptors to signal acute responses to myelin inhibitors. Loss of either receptor alone is sufficient to significantly attenuate myelin inhibitor-elicited growth cone collapse (Chivatakarn et al., 2007; Atwal et al., 2008). To examine whether *PirB* participates in myelin inhibitor-mediated suppression of activity-dependent synaptic plasticity, we used acute hippocampal slices from 6- to 8-week-old *PirB* mutants. As described above, recombinant OMgp was loaded into the recording electrode and locally applied to the dendritic field of CA1 neurons. LTP was induced by two HFS (100 Hz; 1 s; separated by a 10-s interval). Although there was a trend toward decreased LTP in *PirB*<sup>-/-</sup> slices acutely treated with OMgp (fEPSP:  $142 \pm 3\%$ ), it did not reach statistical significance ( $p = 0.07$ ) compared with LTP recorded from *PirB*<sup>-/-</sup> slices in the absence of OMgp (fEPSP:  $157 \pm 6\%$ ) (Fig. 6A,B). Moreover, a direct comparison between the mean fEPSPs at 55–60 min after HFS of *NgR1*<sup>-/-</sup> ( $159 \pm 10\%$ ) and *PirB*<sup>-/-</sup> ( $142 \pm 3\%$ ) slices treated with OMgp did not reveal a significant difference in LTP between these two mutants ( $p = 0.10$ ). Collectively, our data show that loss of *NgR1* largely abrogates the inhibitory effects of OMgp on synaptic strength, whereas loss of *PirB*

leads only to a partial release of the OMgp inhibitory effects on activity-dependent synaptic strength.

### *NgR1*<sup>-/-</sup>, but not *PirB*<sup>-/-</sup>, mice show a hippocampal LTD phenotype

Because our previous studies showed that *NgR1* is necessary for the induction of NMDAR-dependent LTD at CA3–CA1 synapses (H. Lee et al., 2008) and functional depletion of MHC1 molecules (a class of PirB ligands) impairs LTD (Huh et al., 2000), we wondered whether *PirB* plays a role in hippocampal LTD.

As shown by H. Lee et al., 2008, in acute hippocampal slices obtained from juvenile (P15–P17) *NgR1*<sup>-/-</sup> pups, LFS (900 paired pulses delivered at 1 Hz) fails to induce LTD (fEPSP:  $94 \pm 4\%$ ). An identical stimulation protocol induced a significant decrease ( $p < 0.05$ ) in the mean fEPSP in wild-type (fEPSP:  $83 \pm 3\%$ ) and *PirB*<sup>-/-</sup> (fEPSP:  $79 \pm 10\%$ ) slices, resulting in robust LTD (Fig. 6C,D). LTD at CA3–CA1 synapses in *PirB* mutant mice at 55 min after induction is indistinguishable from LTD recordings of age-matched wild-type controls (Fig. 6D). These results suggest that with respect to LTD the functions of *NgR1* and *PirB* in synaptic plasticity can be dissociated. Furthermore, we conclude that loss of *PirB* does not phenocopy the hippocampal LTP or LTD defects reported previously for mice with greatly reduced

cell surface expression of MHC1 molecules (Huh et al., 2000).

Because *NgR1* and PirB functionally collaborate in neurite outgrowth inhibition *in vitro*, we examined whether the combined loss of *NgR1* and *PirB* leads to enhanced LTP reminiscent of  $\beta 2m/TAP1$  or  $CD3\zeta$  mice (Huh et al., 2000). *NgR1*<sup>-/-</sup>; *PirB*<sup>-/-</sup> double mutant mice are viable into adulthood and indistinguishable at the gross anatomical level from wild-type littermate controls (Fig. 6E,F). LTP induced at CA3–CA1 synapses in acute slices of *NgR1*<sup>-/-</sup>; *PirB*<sup>-/-</sup> double mutants (fEPSP:  $156 \pm 5\%$ ) is indistinguishable from that of age-matched wild-type controls (fEPSP:  $162 \pm 14\%$ ). Collectively, these studies show that loss of *NgR1* or *PirB* alone or the combined loss of both receptors does not lead to altered LTP at CA1–CA3 synapses.

### Loss of *NgR1* does not alter glutamate receptor subunit expression *in vivo*

To begin to address how *NgR1* influences activity-dependent synaptic strength, we examined the synaptic distribution of Nogo receptor components and different subunits of the NMDA- and AMPA-type glutamate receptors. Synaptosomes were isolated from neocortical and hippocampal homogenates of 3-, 6-, or 7-week-old *NgR1* wild-type and mutant mice and further separated into extrasynaptic, synaptic junction, presynaptic, and postsynaptic density fractions (Fig. 7).

Analysis of wild-type mouse fractions revealed that *NgR1* is enriched postsynaptically. Antibody specificity was verified by lack of anti-*NgR1* labeling in any of the synaptic fractions isolated




from *NgR1* mutant pups (Fig. 7A). The *NgR1* coreceptors Lingo-1 and p75 are present in hippocampal homogenates (T. H. Lee et al., 1998; Roux et al., 1999; H. Lee et al., 2008). Lingo-1 is heavily enriched in presynaptic fractions; p75, expressed by septo-hippocampal cholinergic fibers (Sugaya et al., 1998), is present in homogenates of *NgR1*<sup>+/+</sup> and *NgR1*<sup>-/-</sup> mice but below detection levels in presynaptic or postsynaptic density fractions (Fig. 7A). Consistent with the observation that loss of *NgR1* does not alter Nogo-A protein expression in brain (Zheng et al., 2005), Nogo-A in hippocampal homogenates and synaptic fractions of *NgR1*<sup>+/+</sup> and *NgR1*<sup>-/-</sup> mice are very similar (Fig. 7A).

We showed previously that FGF2 enhances activity-dependent strength of synaptic transmission in *NgR1* mutant mice. The enhancing effects of FGF2 on LTP in *NgR1*<sup>-/-</sup> mice are FGFR-kinase dependent (H. Lee et al., 2008). Analysis of FGFR1 expression levels revealed that loss of *NgR1* does not result in altered expression or distribution of FGFR1 and its downstream effector FRS2 $\alpha$  (Fig. 7A).

NMDARs are tetramers composed of two obligatory NR1 subunits and two regulatory subunits, usually a combination of NR2A and NR2B. Calcium influx through NMDARs is determined by their subunit distribution. The relative abundance and distribution of NR1 and NR2B in synaptic density fraction is very similar between *NgR1*<sup>+/+</sup> and *NgR1*<sup>-/-</sup> mice, suggesting that loss of *NgR1* does not alter the NR1/NR2B ratio. Repetitive activation of NMDAR leads to insertion of AMPA receptors in the postsynaptic membrane. Loss of *NgR1*<sup>-/-</sup> does not alter expression levels of the AMPAR subunit GluR1 or CaMKII $\alpha$  (Fig. 7A). To confirm the quality of our biochemical preparations, synaptic fractions were analyzed for the presence of several marker proteins, including synaptophysin (extrasynaptic fraction), syntaxin 1A (presynaptic), and PSD-95 (postsynaptic). Together, these results reveal that loss of *NgR1* does not affect expression and distribution of various components of the *NgR1* receptor complex *in vivo*. Furthermore, distribution of several subunits of the NMDA- and AMPA-type glutamate receptors and downstream effectors implicated in synaptic plasticity appears not to be altered.

#### Activation of the mitogen-activated protein kinase ERK1/2 is increased in *NgR1* mutants


Because no apparent changes in protein expression levels or synaptic distribution were detected between *NgR1*<sup>+/+</sup> and *NgR1*<sup>-/-</sup> mice, we next asked whether the activation level of hippocampal or cortical signaling intermediates was altered between the two genotypes. Although protein levels may remain unchanged,




**Figure 6.** Loss of *PirB* attenuates OMgp-mediated suppression of LTP. **A**, Summary of LTP recordings after HFS ( $t = 0$  min) of acute hippocampal slices of 6- to 8-week-old *PirB*<sup>-/-</sup> mice in the absence (blue squares) or presence (red triangles) of acutely applied OMgp. Representative traces before and after HFS are shown as Insets. Calibration is 0.5 mV, 5 ms. **B**, Quantification of mean fEPSPs 55–60 min after HFS from *PirB*<sup>-/-</sup> slices with OMgp (red; mean fEPSP 142  $\pm$  3% of baseline,  $n = 9$  slices/4 animals) is not significantly decreased compared with control *PirB*<sup>-/-</sup> (no OMgp) slices (blue; mean fEPSP 157  $\pm$  8% of baseline,  $n = 14$  slices/6 animals). OMgp-treated *PirB*<sup>-/-</sup> slices showed a trend toward decreased LTP that did not reach statistical significance ( $p = 0.07$ ). **C**, Summary of LTD experiments in acute wild-type (WT), *PirB*<sup>-/-</sup>, and *NgR1*<sup>-/-</sup> hippocampal slices. The same LFS protocol (900 pulses at 1 Hz) that failed to induce LTD in *NgR1*<sup>-/-</sup> slices (red triangles) induced robust and stable LTD in WT (black dots) and *PirB*<sup>-/-</sup> (blue squares) slices. Insets show traces collected before and after LFS. Calibration is 0.5 mV, 5 ms. **D**, Quantification of mean fEPSP data shown in **C** in WT (blue; fEPSP 83  $\pm$  3%,  $n = 9$  slices/4 animals), *PirB*<sup>-/-</sup> (black; fEPSP 79  $\pm$  10%,  $n = 9$  slices/4 animals), and *NgR1*<sup>-/-</sup> (red; fEPSP 94  $\pm$  4% of baseline,  $n = 7$  slices/3 animals) slices at 55–60 min after LFS. **E**, Summary of LTP recordings after HFS ( $t = 0$  min) of wild-type (WT; blue squares) and *NgR1*<sup>-/-</sup>;*PirB*<sup>-/-</sup> double null (red triangles) hippocampal slices. Representative traces before and after HFS are shown as Insets. Calibration is 0.5 mV, 5 ms. **F**, Quantification of mean fEPSP data in **E** in WT (blue; fEPSP 162  $\pm$  14%,  $n = 5$  slices/3 animals) and *NgR1*<sup>-/-</sup>;*PirB*<sup>-/-</sup> (red; fEPSP 156  $\pm$  5%,  $n = 4$  slices/2 animals) slices at 55–60 min after LFS revealed no significant difference. Statistical analysis was performed using Student's *t* test. \* indicates significance,  $p < 0.05$ . n.s. indicates not significantly different. All error bars are SEMs.

many proteins localized to synapses are activated or regulated by phosphorylation of upstream kinases (Lisman, 2003; Sweatt, 2004).

ERK1/2 have previously been shown to regulate activity-dependent synaptic strength in the hippocampus (Sweatt, 2004; Thomas and Huganir, 2004) and visual cortex during OD plasticity (Di Cristo et al., 2001; Takamura et al., 2007). To examine the level of p-ERK1/2 in *NgR1*<sup>-/-</sup> mice, we probed synaptic fractions with a p-ERK1/2-specific antibody. As shown in Figure 7, increased levels of p-ERK were detected in synaptic density fractions derived from *NgR1*<sup>-/-</sup> neocortex (Fig. 7B,C) or hip-



**Figure 7.** Loss of *NgR1* leads to increased phosphorylation of ERK. **A**, Synaptic density fractions were isolated from adult hippocampus of *NgR1* wild-type (+/+) and age-matched mutants (−/−) and subjected to Western blot analysis using antibodies specific for components of the Nogo receptor complex (NgR1, Lingo-1, p75, and Nogo-A), the FGFR1 receptor and the FGFR docking protein FRS2 $\alpha$ , calcium-sensitive kinase CamKII $\alpha$ , and the NMDA and AMPA receptor components NR1, NR2B, and GluR1. For *NgR1*<sup>+/+</sup> and *NgR1*<sup>−/−</sup> fractions, equal amounts of total protein were loaded for hippocampal homogenate (homog), synaptosomes (synapto), extrasynaptic junction (extra SJ), synaptic junction (SJ), presynaptic density fraction (pre), and postsynaptic density fraction (post). To ensure the quality of the biochemical separation of different synaptic fractions, antibodies specific for the synaptic marker proteins synaptophysin (extra-SJ), syntaxin 1A (presynaptic), and PSD-95 (postsynaptic) were used. **B, D**, Immunoblotting of synaptosomal density fractions isolated from adult mouse neocortex (**B**) and hippocampus (**D**) of *NgR1* wild-type (+/+) and *NgR1* mutant (−/−) mice probed with antibodies specific for p-ERK, total ERK1/2 (ERK), and class III  $\beta$ -tubulin. Elevated levels of p-ERK are found in most synaptic fractions of *NgR1*<sup>−/−</sup> mice compared with wild-type controls. **C, E**, Quantification of p-ERK2 immunoreactivity (lower band) on Western blots shown in **B** and **D** revealed a significant increase in the homogenate, synaptosomes, synaptic junction, and postsynaptic density fractions in the neocortex of *NgR1*<sup>−/−</sup> compared with *NgR1*<sup>+/+</sup> (**C**). In the hippocampus synaptosomes and postsynaptic density fractions showed a significant increase of p-ERK2 of



**Figure 8.** CNS myelin and Nogo-66 attenuate BDNF signaling in primary neurons. DIV9 primary cortical neurons were treated with vehicle (control), crude CNS myelin (myelin), or AP-Nogo66 (Nogo-66) for 30 min (lanes 1, 2, and 3). In lanes 4, 5, and 6 neurons were pretreated for 30 min with vehicle, myelin, or Nogo-66 and then incubated for an additional 30 min with BDNF before lysis and immunoblotting. Membranes were probed with antibodies specific for phosphorylated p70S6 kinase (pS6K), pAKT, and pERK1/2. Anti-actin is shown as a loading control. Representative blots of a total  $n = 3$  for each antibody are shown.

pocampus (Fig. 7D,E) compared with littermate wild-type control fractions. Significantly increased levels of p-ERK were seen in several synaptic fractions of *NgR1* mutants compared with the wild-type mice (6–7 weeks old), including synaptosomes, synaptic junction, and postsynaptic density fraction in the neocortex (Fig. 7C) and synaptosomes and postsynaptic density fraction of the hippocampus (Fig. 7E). As was the case for synaptosomes isolated from adult mice, p-ERK in 3-week-old *NgR1*<sup>−/−</sup> mutant fractions was elevated compared with *NgR1*<sup>+/+</sup> controls (data not shown). Together, our findings suggest that ERK signaling is constitutively elevated in the neocortex and hippocampus of *NgR1* mutants.

#### AKT and p70S6-kinase signaling is negatively regulated by crude myelin and Nogo

To examine whether acute treatment of primary neurons with myelin inhibitors leads to altered regulation of signaling pathways previously implicated in neuronal growth and synaptic plasticity, primary cortical neurons (DIV9) were treated with crude CNS myelin or Nogo-66. After an initial increase in p-ERK1/2, prolonged treatment with crude myelin leads to a decrease in p-ERK1/2 (data not shown). As a positive control for ERK1/2 activation, neurons were incubated with BDNF. Interestingly, myelin pretreatment of primary neurons attenuates BDNF-elicited activation of ERK1/2 (Fig. 8). In addition, myelin attenuated BDNF-elicited activation (phosphorylation at Ser473) of AKT and p70S6-kinase (Thr389). This suggests that crude CNS myelin contains factors that attenuate BDNF signaling in primary neurons. Studies with recombinant AP-Nogo-66 showed that, reminiscent of the action of crude CNS myelin, Nogo-66 attenuates BDNF-elicited activation of AKT, p70S6K, and ERK1/2 (Fig. 8). Because BDNF has previously been shown to promote regenerative neuronal growth and sprouting (Zhou and Shine, 2003; Blesch and Tuszynski, 2007; Kwon et al., 2007) and also plays a key role in activity-dependent regulation of synaptic strength (Korte et al., 1995; Rex et al., 2007; Lu et al., 2008), our data suggest that the inhibitory effects of Nogo-66 on synaptic plasticity may at least in part be a reflection of reduced BDNF signaling.

*NgR1*<sup>−/−</sup> mice compared with the corresponding fractions of *NgR1*<sup>+/+</sup> mice. \* $p < 0.05$  statistically significant, Student's *t* test of densitometrically scanned blots from three independent experiments.

Coupled with our previous observation that neuronal NgR1 attenuates FGF2 signaling (H. Lee et al., 2008), the present findings suggest that myelin inhibitors antagonize signaling cascades activated by growth factors.

## Discussion

Here, we report on the identification of Nogo and OMgp as novel regulators of activity-driven synaptic plasticity. In the hippocampus, acute Nogo-66 and OMgp suppress LTP at Schaffer collateral–CA1 synapses, but have no apparent effects on basal synaptic transmission or presynaptic neurotransmitter release. Mechanistic studies revealed that *NgR1* and *PirB*, but not *p75*, are important for ligand-dependent inhibition of LTP. *In vivo*, functional ablation of *NgR1* increases ERK1/2 activation, a signaling intermediate implicated in neuronal growth, OD plasticity, activity-driven synaptic strength, learning, and memory. In primary neurons, Nogo attenuates BDNF-elicited activation of ERK1/2, AKT, and p70S6 kinase. The emerging antagonistic relation between growth factor signaling and myelin inhibitor expression and function suggests a coordinated and highly regulated interaction between these two classes of molecules. The identification of Nogo, OMgp, and their high-affinity receptors NgR1 and PirB as negative regulators of activity-dependent synaptic plasticity suggests novel roles for these molecules beyond their known function in growth inhibition and regulation of neuronal morphology.

### Myelin inhibitors regulate synaptic plasticity

Nogo-A, OMgp, and NgR1 are expressed in the juvenile and adult hippocampus and are abundantly found in presynaptic and postsynaptic density fractions. Loss of *NgR1*, but not *PirB*, impairs LTD at CA3–CA1 synapses. Loss of *NgR1*, *PirB*, or both receptors has no apparent effect on NMDAR-dependent LTP in CA1 neurons. Acute application of Nogo-66 or OMgp to CA3–CA1 synapses attenuates LTP, and the inhibitory effects are no longer observed in *NgR1*<sup>-/-</sup> mice and are reduced in *PirB*<sup>-/-</sup> mice. PPF experiments suggest that Nogo-66 and OMgp decrease LTP via a postsynaptic mechanism. Consistent with this idea, the *NgR1* promoter is highly active in CA1 but not CA3 neurons. Collectively, our studies provide evidence that *NgR1* regulates functional synaptic plasticity in the hippocampus. Because NgR1 expression itself is regulated by neuronal activity (Josephson et al., 2001) and has been shown to regulate the shape of dendritic spines (H. Lee et al., 2008) NgR1 is well suited to link electrical activity to structural changes in mature CNS neurons.

In line with the Allen Brain Atlas (<http://www.brain-map.org>), we found low to moderate expression of *PirB* in principal neurons of the adult mouse hippocampus. Loss of MHC1 surface expression ( $\beta 2m/TAP1$  mutants) results in enhanced LTP and absence of LTD at Schaffer collateral–CA1 synapses (Huh et al., 2000). Loss of *CD3 $\zeta$* , a signaling component of the T cell receptor also expressed in the adult hippocampus, phenocopies the LTP and LTD defects of  $\beta 2m/TAP1$ -deficient mice (Huh et al., 2000). Because other T cell receptor components appear not to be expressed in the adult hippocampus (Syken and Shatz, 2003), and *CD3 $\zeta$*  does not directly interact with MHC1s, we examined whether, like MHC1s, *PirB* participates in CA3–CA1 synaptic plasticity. LTP and LTD in *PirB* mutants is robust and indistinguishable from age-matched wild-type controls. This suggests that *PirB* is not necessary for the induction or expression of LTP or LTD in CA1 neurons. Based on these observations we conclude that MHC1-mediated regulation of synaptic plasticity in CA1 neurons is independent of *PirB*.

### Cross talk between myelin inhibitor and growth factor signaling pathways

Expression of components of the Nogo/NgR1 system is down-regulated by neural activity or exercise (Josephson et al., 2003; Griesbach et al., 2009). Conversely, BDNF (Vaynman and Gomez-Pinilla, 2005) and FGF2 (Gomez-Pinilla et al., 1997) are up-regulated by increased neural activity or exercise. Furthermore, there is evidence for an inverse regulation of myelin inhibitor and growth factor signaling: (i) BDNF antagonizes injury induced up-regulation of Nogo-A in the hippocampus (Chytrova et al., 2008), (ii) preincubation with BDNF renders primary neurons largely resistant to myelin inhibitors (Gao et al., 2003), and (iii) *NgR1* functions as an antagonist of FGF2 (H. Lee et al., 2008).

Here, we expand on those observations and show that Nogo preincubation attenuates BDNF signaling in primary neurons. In the presence of CNS myelin or Nogo-66, BDNF elicited activation of MAP kinase signaling (as assessed by p-ERK1/2) and the phosphatidylinositol 3-kinase (PI3K)-AKT-mTOR-p70S6K pathway (as assessed by p-AKT and p-p70S6K) is decreased. These findings are further corroborated by elevated phosphorylation of ERK1/2 in neocortical and hippocampal extracts of *NgR1*<sup>-/-</sup> mice. Tetanic stimulation results in the secretion of BDNF (Balkowiec and Katz, 2002), and BDNF is important for induction and expression of LTP (Lu et al., 2008). ERK1/2 have been implicated in hippocampal LTP and learning (English and Sweatt, 1997; Kelleher et al., 2004). Recent evidence shows that ERK1/2 participate in synaptic activation of mTOR-p70S6K signaling in LTP (Tsokas et al., 2005, 2007). The canonical pathway for mTOR regulation is independent of ERK1/2 and involves PI3K-PDK1-Akt-dependent inactivation of the mTOR suppressor TSC2 (Manning et al., 2002; Potter et al., 2002), which then leads to mTOR-p70S6K dependent translation of mRNAs and *de novo* protein synthesis at active synapses (Hoeffler and Klann, 2010). It has been proposed that mTOR-mediated protein synthesis in LTP is regulated by coincident activity of the PI3K and ERK1/2 signaling cascades (Tsokas et al., 2007). *In vitro*, Nogo-66 attenuated BDNF-elicited activation of both the AKT-p70S6K and ERK1/2 pathways. We propose that Nogo/NgR1 signaling suppresses BDNF action and thereby attenuates LTP.

Conversely, the failure of CA1 neurons to express LTD in *NgR1* mutants may be a result of elevated AKT-mTOR-p70S6K activity. Previous studies found that PI3K signaling regulates hippocampal LTD (Daw et al., 2002). In *PTEN*<sup>+/-</sup> mice, for example, LTD in CA1 neurons is absent but can be restored by pharmacological inhibition of PI3K (Wang et al., 2006). In primary neurons, Nogo-66 reduces AKT and p70S6K activity in the presence of BDNF. If loss of *NgR1* results in elevated AKT activity at CA1 synapses, this may impair LTD. Although our data suggest a coupling of myelin inhibitor signaling to regulation of synaptic protein translation, additional studies are needed to test this model more directly. One prediction is that inhibition of PI3K in *NgR1*<sup>-/-</sup> slices is sufficient to rescue the observed LTD defect.

### Implications for OD plasticity

Genetic ablation of *Nogo-A/B* or *NgR1* leads to an extension of the CP (McGee et al., 2005). *PirB-TM* mice show enhanced OD plasticity during and after the CP, as assessed by *Arc* expression in the binocular zone of V1 (Syken et al., 2006). This suggests that in the healthy brain physiological signaling by these two receptor systems is important for consolidating neuronal connectivity.

Multiple lines of evidence indicate that intracortical inhibition is an important gatekeeper for onset and closure of the CP. Reducing GABA function by genetic ablation of the GABA-

synthetic enzyme GAD65 or dark-rearing delays CP onset (Hensch et al., 1998). Conversely, enhanced maturation of GABAergic interneurons or local infusion of benzodiazepines increases intracortical inhibition and expedites onset and closure of the CP (Huang et al., 1999; Hensch and Stryker, 2004). In adulthood, pharmacological reduction of intracortical GABA function restores OD plasticity (Maya Vetencourt et al., 2008; Harauzov et al., 2010) and reduced intracortical GABAergic inhibition leads to enhanced LTP-like synaptic plasticity in layer IV of V1 after HFS (Harauzov et al., 2010). Together, these findings argue that modulation of synaptic inhibition in V1 directly affects OD plasticity in response to monocular deprivation. When coupled with our observation that Nogo, OMgp, NgR1, and PirB reduce activity-driven synaptic transmission in the hippocampus, the same molecules may increase the inhibitory tonus in V1 and thereby restrict experience-dependent neuronal plasticity. Thus, myelin inhibitors and their receptors may contribute to the “excitatory-inhibitory balance” in the visual cortex in early postnatal life and more generally influence synaptic homeostasis in different brain regions throughout adulthood.

### Implications for CNS regeneration

Remarkably, the spectrum of extracellular cues that limits OD plasticity at the end of the CP overlaps heavily with the molecular players implicated in restricting neuronal growth and sprouting after injury to the adult mammalian CNS. Beyond the CP, OD plasticity in favor of the nondeprived eye is enhanced by functional ablation of chondroitin sulfate proteoglycans (CSPGs) (Pizzorusso et al., 2002), loss of *Nogo-A/B* or the Nogo receptors *NgR1* and *PirB* (McGee et al., 2005; Syken et al., 2006). In addition to extracellular growth inhibitors, the state of neuronal activity is a critical gatekeeper of OD plasticity. Lowering the inhibitory tonus in the adult visual cortex “reopens” a window of enhanced OD plasticity (Hensch, 2005).

After injury to the adult mammalian CNS, CSPGs and myelin inhibitors limit reactive neuronal sprouting. Injury-induced neuronal sprouting and structural plasticity is enhanced by antagonism of extracellular growth inhibitors (Bradbury et al., 2002; Cafferty et al., 2010; Hoeffler and Klann, 2010; J. K. Lee et al., 2010), elevated neurotrophins (Blesch and Tuszynski, 2009), activation of intrinsic growth programs (Romero et al., 2007; Park et al., 2008), or combinations thereof. Experimentally enhanced neural plasticity often correlates with improved functional outcomes. When combined with task-specific rehabilitative training, performance in trained animals is further improved compared with injured nontrained animals (Girgis et al., 2007; Maier et al., 2008; Garcia-Alias et al., 2009). Thus, like OD plasticity in favor of the nondeprived eye, prolonged neuronal activity appears to beneficially influence the degree of plasticity and functional recovery after injury to the adult mammalian CNS. Injury-induced adaptation of a neural network (spontaneous or enhanced by experimental treatments) leads to substantial reorganization of neuronal structure at multiple levels. At the same time, injury also causes a range of functional synaptic changes. We propose that antagonism of myelin inhibitors, including Nogo and OMgp, may not only lower the growth inhibitory milieu of adult CNS tissue but simultaneously lower the inhibitory tonus in neuronal networks. As a result, increased neuronal activity and synaptic transmission may enable activity-driven reorganization and refinement of injured neural networks that result in improved behavioral outcomes.

Collectively, our studies identify Nogo, OMgp, and their high-affinity receptors as negative regulators of activity-driven synap-

tic strength and thus contribute to our understanding of the role of these molecules in neural health, injury, and disease.

### References

- Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, Shatz C, Tessier-Lavigne M (2008) PirB is a functional receptor for myelin inhibitors of axonal regeneration. *Science* 322:967–970.
- Balkowiec A, Katz DM (2002) Cellular mechanisms regulating activity-dependent release of native brain-derived neurotrophic factor from hippocampal neurons. *J Neurosci* 22:10399–10407.
- Bareyre FM, Kerschensteiner M, Raineteau O, Mettenleiter TC, Weinmann O, Schwab ME (2004) The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. *Nat Neurosci* 7:269–277.
- Barrett GL, Greferath U, Barker PA, Trieu J, Bennie A (2005) Co-expression of the P75 neurotrophin receptor and neurotrophin receptor-interacting melanoma antigen homolog in the mature rat brain. *Neuroscience* 133:381–392.
- Barrette B, Vallières N, Dubé M, Lacroix S (2007) Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system. *Mol Cell Neurosci* 34:519–538.
- Blesch A, Tuszynski MH (2007) Transient growth factor delivery sustains regenerated axons after spinal cord injury. *J Neurosci* 27:10535–10545.
- Blesch A, Tuszynski MH (2009) Spinal cord injury: plasticity, regeneration and the challenge of translational drug development. *Trends Neurosci* 32:41–47.
- Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. *Nature* 361:31–39.
- Boulanger LM (2009) Immune proteins in brain development and synaptic plasticity. *Neuron* 64:93–109.
- Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature* 416:636–640.
- Cafferty WB, Duffy P, Huebner E, Strittmatter SM (2010) MAG and OMgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma. *J Neurosci* 30:6825–6837.
- Chen Y, Stevens B, Chang J, Milbrandt J, Barres BA, Hell JW (2008) NS21: re-defined and modified supplement B27 for neuronal cultures. *J Neurosci Methods* 171:239–247.
- Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ (2007) The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. *J Neurosci* 27:7117–7124.
- Chytrova G, Ying Z, Gomez-Pinilla F (2008) Exercise normalizes levels of MAG and Nogo-A growth inhibitors after brain trauma. *Eur J Neurosci* 27:1–11.
- Corriveau RA, Huh GS, Shatz CJ (1998) Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. *Neuron* 21:505–520.
- Datwani A, McConnell MJ, Kanold PO, Micheva KD, Busse B, Shamloo M, Smith SJ, Shatz CJ (2009) Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity. *Neuron* 64:463–470.
- Daw MI, Bortolotto ZA, Saulle E, Zaman S, Collingridge GL, Isaac JT (2002) Phosphatidylinositol 3 kinase regulates synapse specificity of hippocampal long-term depression. *Nat Neurosci* 5:835–836.
- Di Cristo G, Berardi N, Cancedda L, Pizzorusso T, Putignano E, Ratto GM, Maffei L (2001) Requirement of ERK activation for visual cortical plasticity. *Science* 292:2337–2340.
- Dorfman JR, Zerrahn J, Coles MC, Raulet DH (1997) The basis for self-tolerance of natural killer cells in beta2-microglobulin- and TAP-1- mice. *J Immunol* 159:5219–5225.
- English JD, Sweatt JD (1997) A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. *J Biol Chem* 272:19103–19106.
- Florence SL, Taub HB, Kaas JH (1998) Large-scale sprouting of cortical connections after peripheral injury in adult macaque monkeys. *Science* 282:1117–1121.
- Gao Y, Nikulina E, Mellado W, Filbin MT (2003) Neurotrophins elevate cAMP to reach a threshold required to overcome inhibition by MAG through extracellular signal-regulated kinase-dependent inhibition of phosphodiesterase. *J Neurosci* 23:11770–11777.

- García-Álías G, Barkhuysen S, Buckle M, Fawcett JW (2009) Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation. *Nat Neurosci* 12:1145–1151.
- Giger RJ, Wolfer DP, De Wit GM, Verhaagen J (1996) Anatomy of rat semaphorin III/collapsin-1 mRNA expression and relationship to developing nerve tracts during neuroembryogenesis. *J Comp Neurol* 375:378–392.
- Gil V, Bichler Z, Lee JK, Seira O, Llorens F, Bribian A, Morales R, Claverol-Tinture E, Soriano E, Sumoy L, Zheng B, Del Río JA (2010) Developmental expression of the oligodendrocyte myelin glycoprotein in the mouse telencephalon. *Cereb Cortex* 20:1769–1779.
- Girgis J, Merrett D, Kirkland S, Metz GA, Verge V, Fouad K (2007) Reaching training in rats with spinal cord injury promotes plasticity and task specific recovery. *Brain* 130:2993–3003.
- Gómez-Pinilla F, Dao L, So V (1997) Physical exercise induces FGF-2 and its mRNA in the hippocampus. *Brain Res* 764:1–8.
- Griesbach GS, Hovda DA, Gomez-Pinilla F (2009) Exercise-induced improvement in cognitive performance after traumatic brain injury in rats is dependent on BDNF activation. *Brain Res* 1288:105–115.
- Grünewald E, Kinnell HL, Porteous DJ, Thomson PA (2009) GPR50 interacts with neuronal Nogo-A and affects neurite outgrowth. *Mol Cell Neurosci* 42:363–371.
- Harauzov A, Spolidoro M, DiCristo G, De Pasquale R, Cancedda L, Pizzorusso T, Viegi A, Berardi N, Maffei L (2010) Reducing intracortical inhibition in the adult visual cortex promotes ocular dominance plasticity. *J Neurosci* 30:361–371.
- Hensch TK (2005) Critical period plasticity in local cortical circuits. *Nat Rev Neurosci* 6:877–888.
- Hensch TK, Stryker MP (2004) Columnar architecture sculpted by GABA circuits in developing cat visual cortex. *Science* 303:1678–1681.
- Hensch TK, Fagiolini M, Mataga N, Stryker MP, Baekkeskov S, Kash SF (1998) Local GABA circuit control of experience-dependent plasticity in developing visual cortex. *Science* 282:1504–1508.
- Hoeffler CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. *Trends Neurosci* 33:67–75.
- Holtmaat A, Svoboda K (2009) Experience-dependent structural synaptic plasticity in the mammalian brain. *Nat Rev Neurosci* 10:647–658.
- Huang ZJ, Kirkwood A, Pizzorusso T, Porciatti V, Morales B, Bear MF, Maffei L, Tonegawa S (1999) BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. *Cell* 98:739–755.
- Huber AB, Weinmann O, Brösamle C, Oertle T, Schwab ME (2002) Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. *J Neurosci* 22:3553–3567.
- Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ (2000) Functional requirement for class I MHC in CNS development and plasticity. *Science* 290:2155–2159.
- Hunt D, Mason MR, Campbell G, Coffin R, Anderson PN (2002) Nogo receptor mRNA expression in intact and regenerating CNS neurons. *Mol Cell Neurosci* 20:537–552.
- Josephson A, Widenfalk J, Widmer HW, Olson L, Spenger C (2001) Nogo mRNA expression in adult and fetal human and rat nervous tissue and in weight drop injury. *Exp Neurol* 169:319–328.
- Josephson A, Trifunovski A, Schele C, Widenfalk J, Wahlestedt C, Bren S, Olson L, Spenger C (2003) Activity-induced and developmental downregulation of the Nogo receptor. *Cell Tissue Res* 311:333–342.
- Karlén A, Karlsson TE, Mattsson A, Lundströmer K, Codeluppi S, Pham TM, Bäckman CM, Ogren SO, Aberg E, Hoffman AF, Sherling MA, Lupica CR, Hoffer BJ, Spenger C, Josephson A, Brené S, Olson L (2009) Nogo receptor 1 regulates formation of lasting memories. *Proc Natl Acad Sci U S A* 106:20476–20481.
- Katz LC, Shatz CJ (1996) Synaptic activity and the construction of cortical circuits. *Science* 274:1133–1138.
- Kelleher RJ 3rd, Govindarajan A, Jung HY, Kang H, Tonegawa S (2004) Translational control by MAPK signaling in long-term synaptic plasticity and memory. *Cell* 116:467–479.
- Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T (1995) Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. *Proc Natl Acad Sci U S A* 92:8856–8860.
- Kwon BK, Liu J, Lam C, Plunet W, Oschipok LW, Hauswirth W, Di Polo A, Blesch A, Tetzlaff W (2007) Brain-derived neurotrophic factor gene transfer with adeno-associated viral and lentiviral vectors prevents rubrospinal neuronal atrophy and stimulates regeneration-associated gene expression after acute cervical spinal cord injury. *Spine* 32:1164–1173.
- Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y, Yeh HH, Shrager P, Giger RJ (2008) Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. *J Neurosci* 28:2753–2765.
- Lee JK, Case LC, Chan AF, Zhu Y, Tessier-Lavigne M, Zheng B (2009) Generation of an OMgp allelic series in mice. *Genesis* 47:751–756.
- Lee JK, Geoffroy CG, Chan AF, Tolentino KE, Crawford MJ, Leal MA, Kang B, Zheng B (2010) Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. *Neuron* 66:663–670.
- Lee KF, Li E, Huber LJ, Landis SC, Sharpe AH, Chao MV, Jaenisch R (1992) Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. *Cell* 69:737–749.
- Lee TH, Kato H, Pan LH, Ryu JH, Kogure K, Itoyama Y (1998) Localization of nerve growth factor, trkA and P75 immunoreactivity in the hippocampal formation and basal forebrain of adult rats. *Neuroscience* 83:335–349.
- Lisman J (2003) Actin's actions in LTP-induced synapse growth. *Neuron* 38:361–362.
- Lu Y, Christian K, Lu B (2008) BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? *Neurobiol Learn Mem* 89:312–323.
- Maier IC, Baumann K, Thallmair M, Weinmann O, Scholl J, Schwab ME (2008) Constraint-induced movement therapy in the adult rat after unilateral corticospinal tract injury. *J Neurosci* 28:9386–9403.
- Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberlin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol Cell* 10:151–162.
- Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, Castrén E, Maffei L (2008) The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science* 320:385–388.
- McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM (2005) Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. *Science* 309:2222–2226.
- Meng Y, Zhang Y, Jia Z (2003) Synaptic transmission and plasticity in the absence of AMPA glutamate receptor GluR2 and GluR3. *Neuron* 39:163–176.
- Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M, He Z (2008) Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. *Science* 322:963–966.
- Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan WS, Arndt K, Frank M, Gordon RE, Gawinowicz MA, Zhao Y, Colman DR (2001) The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. *Neuron* 32:63–77.
- Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L (2002) Reactivation of ocular dominance plasticity in the adult visual cortex. *Science* 298:1248–1251.
- Potter CJ, Pedraza LG, Xu T (2002) Akt regulates growth by directly phosphorylating Tsc2. *Nat Cell Biol* 4:658–665.
- Rex CS, Lin CY, Kramár EA, Chen LY, Gall CM, Lynch G (2007) Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. *J Neurosci* 27:3017–3029.
- Robak LA, Venkatesh K, Lee H, Raiker SJ, Duan Y, Lee-Osbourne J, Hofer T, Mage RG, Rader C, Giger RJ (2009) Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. *J Neurosci* 29:5768–5783.
- Romero MI, Lin L, Lush ME, Lei L, Parada LF, Zhu Y (2007) Deletion of Nfl in neurons induces increased axon collateral branching after dorsal root injury. *J Neurosci* 27:2124–2134.
- Roux PP, Colicos MA, Barker PA, Kennedy TE (1999) p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure. *J Neurosci* 19:6887–6896.
- Schubert V, Dotti CG (2007) Transmitting on actin: synaptic control of dendritic architecture. *J Cell Sci* 120:205–212.
- Schulz PE, Cook EP, Johnston D (1994) Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. *J Neurosci* 14:5325–5337.
- Sojka DK, Hughson A, Sukiennicki TL, Fowell DJ (2005) Early kinetic window of target T cell susceptibility to CD25+ regulatory T cell activity. *J Immunol* 175:7274–7280.
- Sugaya K, Greene R, Personett D, Robbins M, Kent C, Bryan D, Skiba E,

- Gallagher M, McKinney M (1998) Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline. *Neurobiol Aging* 19:351–361.
- Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. *Curr Opin Neurobiol* 14:311–317.
- Syken J, Shatz CJ (2003) Expression of T cell receptor beta locus in central nervous system neurons. *Proc Natl Acad Sci U S A* 100:13048–13053.
- Syken J, Grandpre T, Kanold PO, Shatz CJ (2006) PirB restricts ocular-dominance plasticity in visual cortex. *Science* 313:1795–1800.
- Takai T (2005) Paired immunoglobulin-like receptors and their MHC class I recognition. *Immunology* 115:433–440.
- Takamura H, Ichisaka S, Hayashi C, Maki H, Hata Y (2007) Monocular deprivation enhances the nuclear signalling of extracellular signal-regulated kinase in the developing visual cortex. *Eur J Neurosci* 26:2884–2898.
- Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. *Nat Rev Neurosci* 5:173–183.
- Tropea D, Van Wart A, Sur M (2009) Molecular mechanisms of experience-dependent plasticity in visual cortex. *Philos Trans R Soc Lond B Biol Sci* 364:341–355.
- Tsokas P, Grace EA, Chan P, Ma T, Sealfon SC, Iyengar R, Landau EM, Blitzer RD (2005) Local protein synthesis mediates a rapid increase in dendritic elongation factor 1A after induction of late long-term potentiation. *J Neurosci* 25:5833–5843.
- Tsokas P, Ma T, Iyengar R, Landau EM, Blitzer RD (2007) Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of rapamycin pathway. *J Neurosci* 27:5885–5894.
- Ujike A, Takeda K, Nakamura A, Ebihara S, Akiyama K, Takai T (2002) Impaired dendritic cell maturation and increased T(H)2 responses in PIR-B(–/–) mice. *Nat Immunol* 3:542–548.
- Vaynman S, Gomez-Pinilla F (2005) License to run: exercise impacts functional plasticity in the intact and injured central nervous system by using neurotrophins. *Neurorehabil Neural Repair* 19:283–295.
- Venkatesh K, Chivatakarn O, Lee H, Joshi PS, Kantor DB, Newman BA, Mage R, Rader C, Giger RJ (2005) The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. *J Neurosci* 25:808–822.
- Venkatesh K, Chivatakarn O, Sheu SS, Giger RJ (2007) Molecular dissection of the myelin-associated glycoprotein receptor complex reveals cell type-specific mechanisms for neurite outgrowth inhibition. *J Cell Biol* 177:393–399.
- Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, Strittmatter SM (2002) Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. *J Neurosci* 22:5505–5515.
- Wang Y, Cheng A, Mattson MP (2006) The PTEN phosphatase is essential for long-term depression of hippocampal synapses. *Neuromolecular Med* 8:329–336.
- Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B (2005) Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. *Nat Neurosci* 8:1069–1077.
- Xie F, Zheng B (2008) White matter inhibitors in CNS axon regeneration failure. *Exp Neurol* 209:302–312.
- Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. *Nat Rev Neurosci* 7:617–627.
- Yuste R, Bonhoeffer T (2001) Morphological changes in dendritic spines associated with long-term synaptic plasticity. *Annu Rev Neurosci* 24:1071–1089.
- Zagrebelsky M, Holz A, Dechant G, Barde YA, Bonhoeffer T, Korte M (2005) The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. *J Neurosci* 25:9989–9999.
- Zheng B, Atwal J, Ho C, Case L, He XL, Garcia KC, Steward O, Tessier-Lavigne M (2005) Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. *Proc Natl Acad Sci U S A* 102:1205–1210.
- Zhou L, Shine HD (2003) Neurotrophic factors expressed in both cortex and spinal cord induce axonal plasticity after spinal cord injury. *J Neurosci Res* 74:221–226.